Dr. Dimitrios Zeugolis is a Lecturer in Biomedical Engineering (Biomaterials) at NUI Galway. He has a PhD from the University of Northampton and was a Post-Doctoral Fellow at the National University of Singapore. In 2007, he joined NUI Galway as a Government of Ireland Research Fellow. Since 2013, he is visiting Professor at TEI of Epirus, Greece. He established the Regenerative, Modular & Developmental Engineering Laboratory (REMODEL) and is a Principal Investigator at the Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM) at NUI Galway. He is President of Matrix Biology Ireland (MBI) society; member of various committees, councils and review boards (TERMIS, ORS, E-MRS, BBSRC). Dimitrios has authored >70 peer-reviewed articles, >350 peer-reviewed conference publications, 1 peer-reviewed book and 12 peer-reviewed book chapters and has been awarded >€15 million as Principal Investigator from national (e.g. Science Foundation Ireland, Health Research Board, Irish Research Council, Enterprise Ireland, Teagasc) and international (e.g. European Commission 7th Framework Programme, European Commission Horizon 2020 Programme) funding agencies and direct industry contribution (e.g. Medtronic, Stem Cell Technologies, Viscus Biologics). He has secured 2 patents and was co-founder of Vornia Biomaterials Ltd.



REMODEL operates at the forefront of scientific research and technological innovation to generate new knowledge, technologies, tools and discoveries that will improve human lives. REMODEL is funded by a diverse range of national and international funding agencies to take concepts through the various technology readiness levels and address unmet clinical needs in the area of soft and hard tissue repair and regeneration. REMODEL (a) uses bottom up and to-down approaches to build nano-textured constructs that closely imitate the properties of native extracellular matrix assemblies; (b) utilises recent advancements in scaffold functionalisation, through incorporation of biophysical cues, biological beacons and biochemical signals, to provide therapeutic interventions for the treatment of soft and hard tissue injuries; and (c) investigates how modulation of the in vitro microenvironment will facilitate either permanently differentiated cell phenotype preservation or stem cell lineage commitment and enable wide acceptance and clinical translation of cell-based therapies.